Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
UNCY
Strong SellSinkerUnicycive Therapeutics, Inc. · Healthcare · United States · $144M · Avg Vol: $4M/d
COMPANY DESCRIPTION
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing novel treatments for patients with kidney disease and related conditions. Its competitive moat is derived from a pipeline of proprietary drug candidates, including a late-stage asset for hyperphosphatemia in chronic kidney disease patients on dialysis, addressing significant unmet medical needs. Unicycive is positioned as an emerging biopharmaceutical firm dedicated to nephrology innovations.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0M | 0.7M | 0 | 0 | -29.0% | — | 0.3M | 145.4M | 283.1% |
| EPS | -0.67 | -1.62 | -2.35 | -1.67 | — | -1.75 | -1.21 | 1.41 | — |
| Shares | 27.4M | 27.4M | 27.4M | 22.1M | -19.3% | 27.4M | — | — | — |
| Debt | 0.2M | 0.8M | 0.8M | 0.2M | -0.3% | 0.7M | — | — | — |
| Equity | -0.5M | -3.8M | 7.4M | 30.2M | 306.4% | — | — | — | — |
| Op CF | -15.7M | -18.3M | -28.6M | -31.3M | — | -27.8M | — | — | — |
| Inv CF | -2.0K | -12.0K | -72.0K | -12.1M | — | — | — | — | — |
| Fin CF | -0.5M | 27.5M | 45.1M | 46.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UNCY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc.(you) | $144M | 11 | Strong Sell |
| CNTB | Connect Biopharma Holdings Limited | $140M | 10 | Strong Sell |
| INDP | Indaptus Therapeutics, Inc. | $152M | 10 | Strong Sell |
| KPTI | Karyopharm Therapeutics Inc. | $168M | 11 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 12 | Strong Sell |
| TNYA | Tenaya Therapeutics, Inc. | $155M | 14 | Strong Sell |
| OTLK | Outlook Therapeutics, Inc. | $156M | 14 | Strong Sell |
| LENZ | LENZ Therapeutics, Inc. | $161M | 14 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 7 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%